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ABSTRACT 
 
Background: The increase use of highly active antiretroviral therapy (HAART) 
among patients with HIV infection and AIDS has led to increasing reports of 
metabolic abnormalities such as diabetes mellitus, hypertension, dyslipidaemia and 
obesity. Therefore, it is important to explore the burden of these diseases among 
HIV infected patients.  
Objectives: To determine the burden of metabolic diseases (hypertension, diabetes, 
obesity and dyslipidaemia) in patients attending HIV clinic at the Charlotte Maxeke 
Johannesburg Academic Hospital (JHBH). 
Methodology: It was a cross-sectional study. The study population included patients 
attending JHBH HIV clinic and on HAART for more than one year. A sample size of 
304 patients, including 237 females and 67 males partook in this study. 
Anthropometric measurements were taken from patients and blood samples of these 
patients were sent to laboratory for lipograms, HbA1c, random glucose, CD4 
lymphocytes counts as well as HIV viral load testing. The data was analysed with 
standard statistical software Epi-info version 6.0. Both descriptive and analytical 
statistics was used.    
Results: The prevalence of metabolic syndrome according to the IDF was 20.4 %; 
obesity (BMI 30 kg/m2) was 16.8% and patients that were overweight (BMI > 25 
kg/m2 and BMI < 29.9 kg/m2) was 28.6%; hypercholesterolemia (TC  5.0 mmol/l) = 
35.5%; HDL< 1.29 mmol\L in females was 58% and HDL <1.04 mmol/l in males was 
36%; elevated triglycerides  1.7 mmol/l was 30% and only 16% was classified as 
being hypertensive (BP  140/90 mmHg and / or on Hypertensive medication). The 
majority of the patients (86.2%) had a CD4 lymphocyte count  200 X 106  cells/l  
and 84% of patients had less than detectable limits for viral loads (VL< 40 copies / 
µl), which has been reported as optimum levels for metabolic diseases in HAART 
recipients.   
Conclusion: These results clearly indicate that there is a growing burden of 
metabolic diseases among HIV patients on HAART attending the Johannesburg 
hospital HIV clinic. The current study also indicates that the metabolic disturbances 
are more frequent in women than in men, except for hypertension. 
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GLOSSARY OF TERMS 
 
Diabetes and abnormal glucose metabolism: Patients can be categorised as 
having glucose disorders if they have a fasting plasma glucose  110 mg/dl (6.1 
mmol/l) or hyperglycemia defined as random glucose tolerance test  140 mg/dL 
(11.1 mmol/l) or HBA1c levels >7% (1). The World Health Organization (WHO) 
defines impaired glucose tolerance as fasting glucose > 110 mg/dL and diabetes as 
> 126 mg/dL (2).  
 
Dyslipidaemia: These have been identified by increased total and low density 
lipoprotein (LDL) cholesterol, decreased high density lipoprotein (HDL) cholesterol 
and mixed forms (3). It can be defined by the occurrence of any one of the following: 
total cholesterol (TC)  240 mg/dl (>6.2 mmol/l), LDL cholesterol  160 mg/dl (4.1 
mmol/l), or triglycerides  200 mg/L (>1.7 mmol/l) (1). 
 
Insulin Resistance: refers to the reduced action of circulating insulin to induce 
uptake of glucose into cells, where glucose serves as a major substrate for cellular 
function (4). 
 
Metabolic syndrome: Metabolic syndrome (also called syndrome X), is 
phenotypically closely associated with visceral obesity, metabolic deregulation, and 
risk for diabetes mellitus and cardiovascular disease (4). 
Metabolic syndrome according to the IDF and NCEP (ATPIII) criteria:  
IDF criteria includes waist circumference >80 cm in women and >94 cm in men plus 
two of the following: triglycerides > 1.7 mmol/l, HDL <1.29 mmol/l, fasting glucose, 
5.6 mmol/l, systolic blood pressure 130 mmHg, or diastolic blood pressure 85 
mmHg (5;6). 
NCEP (ATPIII) criteria requires three or more of the following: waist circumference 
>88 cm in women and> 102 cm in men, triglycerides > 1.7 mmol/l, HDL <1.20 mmol/l 
in women or <1.04 mmol/l in men, fasting glucose  6.1 mmol/l, or blood pressure 
>130/85 mmHg (6). 
 
  xii   
 
Obesity and overweight: BMI is defined as the weight in kilograms divided by the 
square of the height in meters (kg/m2). The WHO suggested following weight 
categories (7):  
• Under weight (< 18.5 kg/m2)  
• Normal weight (18.5 to 24.9 kg/m2)  
• Over weight (25 to 29.9 kg/m2) and  
• Obese (30 kg/m2 or more). 
 
Population: The complete collection of elements, groups, or individuals to be 
studied  
 
Risk: The probability that an event will occur, e.g. that an individual will become ill or 
die within a stated period of time or age. 
 
Risk Factor: An aspect of personal behaviour or lifestyle, an environmental 
exposure, or an inborn or inherited characteristic that is associated with an increased 
occurrence of disease or other health-related event or condition 
 
Prevalence: The number or proportion of cases or events or conditions in a given 
population. Prevalence is a mathematical quantity that describes the presence of a 
disease Y in a population. It is the proportion of persons in the population with the 
disease Y: 
 
Sample: A selected subset of a population. A sample may be random or non-
random and it may be representative or non-representative 
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CHAPTER 1 
 
INTRODUCTION 
 
 
The purpose of this study was to determine the burden of metabolic diseases 
(hypertension, diabetes, obesity and dyslipidaemia) among HIV patients on 
HAART in patients attending HIV clinics at the Charlotte Maxeke 
Johannesburg Academic Hospital (JHBH). 
 
1.1 BACKGROUND  
 
South Africa has one of the highest prevalence of Human Immunodeficiency 
Virus (HIV) infection in the world (8), with over 5 million people infected with 
the virus, which accounts for more than 10% of the countries’ total population 
(9). This has led to high morbidity and mortality rates. In 2004, the South 
African government has approved the roll out of antiretroviral therapy (ART) to 
all HIV infected people who fulfil certain criteria. Highly active antiretroviral 
therapy (HAART) has shown to increase the life expectancy of HIV infected 
patients and their overall health outcome (10). However, the use of protease 
inhibitor (PI), which is part of the HAART and ART regiment, has been 
associated with various chronic diseases like metabolic diseases (11). 
Therefore, it is important to explore the burden of these diseases among HIV 
infected patients.  
 
1.2 JUSTIFICATION FOR THE STUDY  
 
The quadruple burden of disease in South Africa (figure 1.1) indicates that 
HIV/ADS (29.8%), followed by cardiovascular disease (16.6%) was the two 
main causes of death in the year 2000, followed by infectious and parasitic 
diseases (10.3 %), and injuries, both intentional (7.0%) and unintentional 
(5.4%) (12). This data, on cardiovascular diseases, indicates that there is a 
high prevalence of metabolic diseases in South Africa.  
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(Bradshaw et al. 2003) 
Figure 1.1: Cause of death by category, in South Africa 2000 
 
However, the recent introduction of HAART for HIV positive patients exposes 
them to cardio-metabolic diseases. However, no study has explored this 
problem in South Africa. 
 
1.3 PROBLEM STATEMENT  
 
The burden of metabolic diseases among HIV positive patients in South Africa 
has not been fully explored. 
 
1.4 STUDY OBJECTIVES 
  
1.4.1 BROAD OBJECTIVE  
 
To determine the health burden of metabolic diseases (hypertension, 
diabetes, obesity and dyslipidaemia) in patients attending HIV clinic at the 
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Charlotte Maxeke Academic Johannesburg Hospital (JHBH). 
 
1.4.2 SPECIFIC OBJECTIVES 
 
1) To determine the prevalence of metabolic diseases (hypertension, 
diabetes, obesity and dyslipidaemia) in patients attending the HIV 
clinics at JHBH  
 
2) To determine the prevalence of metabolic syndrome among patients 
attending the HIV clinics at JHBH  
 
3) To determine the association between specific risk factors (such as: 
age, gender, CD4 lymphocyte count, viral load) and  metabolic 
syndrome in HIV infected patients  
 
1.5  SUBSEQUENT CHAPTERS OF THE REPORT  
 
The background to the research has been discussed and the objectives were 
defined up to this point. The subsequent chapters will focus on:  
 
Chapter two: Literature review. 
The purpose of the literature review is to elaborate on key concepts and to 
identify related prevalence and risk factors that has been documented in 
similar studies.  
 
Chapter three: Methodology  
This chapter describes the methodology that was used to conduct this study 
and elaborates on the sampling method, scope, data collection as well as the 
pilot study.  
 
Chapter Four: Results  
The findings of the results are contained in this chapter and are aligned with 
the objective of this study.  
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Chapter Five: Discussion 
The results and the literature review are integrated in this chapter in order to 
address the problem statement and the objectives of the study.  
 
Chapter six: Conclusion and recommendations  
This chapter concludes the research report and draws conclusions from the 
research data and makes recommendations regarding the need to test HIV 
positive patients for metabolic related diseases. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
In this chapter, relevant literature related to metabolic diseases and 
associations with HIV and HAART are discussed.  
 
2.1 INTRODUCTION  
 
At the end of 2007 the United Nations Programme on HIV/AIDS (UNAIDS) 
and the World Health Organization (WHO) jointly estimated that 33.2 million 
people worldwide were infected with HIV. This data also confirmed the 
disproportionate impact of HIV/AIDS on sub-Saharan Africa, in that the sub-
Saharan Africa accounts for 68% of the persons living with HIV/AIDS 
worldwide and accounts for 76% of deaths due to AIDS. (9)  
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Table 2.1: Global HIV statistic  
  People living with 
HIV  
New infections 
2007 
AIDS deaths 
2007 
Adult 
prevalence % 
22 million  1.9 million  1.5 million  5% Sub-Saharan 
Africa  [20.5 – 23.6 million]  [1.6– 2.1 million]  [1.3 – 1.7 million]  [4.6% – 5.4%]  
4.2 million  330 000  340 000  0.30% South and 
South-East 
Asia  [3.5 – 5.3 million]  [150 000 – 590 
000]  
[230 000 – 450 
000]  
[0.2% – 0.4%]  
740 000  52 000  40 000  0.10% East Asia  
[480 000 – 1.1 million]  [29 000 – 84 000]  [24 000 – 63 000]  [<0.1% – 0.2%]  
1.7 million  140 000  63 000  0.50% Latin America  
[1.5 – 2.1 million]  [88 000 – 190 000]  [49 000 – 98 000]  [0.4% – 0.6%]  
1.2 million  54 000  23 000  0.60% North 
America  [760 000 – 2 million]  [9600 – 130 000]  [9100 – 55 000]  [0.4% – 1.0%]  
730 000  27 000  8000 0.30% Western and 
Central 
Europe  [580 000 – 1 million]  [14 000 – 49 000]  [4800 – 17 000]  [0.2% – 0.4%]  
1.5 million  110 000  58 000  0.80% Eastern 
Europe, 
Central Asia  [1.1 – 1.9 million]  [67 000 – 180 000]  [41 000 – 88 000]  [0.6% – 1.1%]  
230 000  20 000  14 000  1.10% Caribbean  
[210 000 – 270 000]  [16 000 – 25 000]  [11 000 – 16 000]  [1.0% – 1.2%]  
380 000  40 000  27 000  0.30% Middle East 
and North 
Africa  [280 000 – 510 000]  [20 000 – 66 000]  [20 000 – 35 000]  [0.2% – 0.4%]  
74 000  13 000  1000 0.40% Oceania  
[66 000 – 93 000]  [12 000 – 15 000]  [<1000 – 1400]  [0.3% – 0.5%]  
33 million  2.7 million  2 million  0.80% Total  
[30.3 – 36.1 million]  [2.2 – 3.2 million]  [1.8 – 2.3 million]  [0.7% – 0.9%]  
[Source: Report on the global AIDS epidemic 2008, August 2008] 
 
South Africa has been deemed the country with the highest prevalence of HIV 
in the world, with over 5 million people infected with the virus, which accounts 
for more than 10% of the countries’ total population (9). The prevalence of 
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HIV/AIDS in the province of Gauteng is estimated 15% of the population in 
that province. (The province where this study has been conducted) (Figure 
2.1) 
 
Figure 2.1: Republic of South Africa 
 
The prevalence of HIV in South Africa is described in Figure 2.2.  
 
(ASSA2003 (full) AIDS and Demographic model available on: www.actuarialsociety.org.za) 
Figure 2.2: Population distribution on HIV Prevalence in South Africa 
 
Highly active antiretroviral therapy (HAART) has been used as treatment for 
people infected with HIV. Highly active antiretroviral therapy has significantly 
improved the life-expectancy of people living with HIV in that it restores 
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immune system functions, and suppress viral load replications (4). HAART 
can be divided into five drug classes: protease inhibitors (PI) (indinavir, 
ritonavir, fosamprenavir, saquinavir, tipranavir and darunavir), Nucleoside 
reverse transcriptase inhibitors (NTRIs) (Stavudine, zidovudine, lamivudine, 
abacavir, didanosine, tenofovir and emtricitabine), non-nucleoside reverse 
transcriptase inhibitors (NNTRIs) (sfaviranz and nevirapine), entry class 
inhibitors (fusion inhibitors: enfuvirtide; and CCR5 inhibitors: maraviroc) and 
integrase inhibitors (raltegravir) (4). 
 
The increase use of (HAART) among patients with HIV infection has led to 
increasing reports of metabolic diseases such as diabetes, hypertension, 
dyslipidaemia, obesity (1;13). The Table 2.2 depicts some of the known 
adverse effects associated with HAART (14). These metabolic diseases is 
underpinned by insulin resistance, which has been found to be an adverse 
side effect of protease inhibitors (4;15-17).   
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Table 2.2: HIV regiment and associated adverse effect 
Regiment  Associated Adverse side effect  
IDV + ZDV + 3TCIDV 
+ d4T 
patients developed abnormal accumulation of fat over 
shoulders and neck (buffalo hump); increased breast size 
and abdominal girth 
3TC + d4T + IDV Swelling in breast noted, chest measurement increased; 
therapy continued and 
chest size increased 5 months post-IDV initiation; associated 
with breast pain; oedematous skin encompassing breasts, 
increased abdominal girth, thinning of buttocks and thighs.  
HIV-infected patients 
with buffalo hump 
receiving RTIs with a 
PI (IDVor NFV)  
DEXA showed that patients  with buffalo hump had 
significantly greater proportion of truncal fat than control 
patients 
ZDV + 3TC + IDV 
(800 
mg three times daily) 
 
Fat wasting in arms, buttocks, and legs along with central 
obesity and enlargement of 
cervicodorsal fat pad. DEXA confirmed loss of 
body fat. No changes in muscle mass or strength. 
No abdominal organomegaly, mass, or ascites. Changes 
progressed over 19 months  of monitoring; 
Normal fasting morning plasma cortisol; elevated TG, 
cholesterol, C peptide concentrations; impaired glucose 
tolerance 
Two NRTIs + One 
PI; Two NRTIs 
Specific drugs and 
dosages not stated 
 significant breast  enlargement in women (>2 bra sizes), 
increase in abdominal girth, reduction in fat mass of calves 
and thighs, no changes in total body weight; DEXA showed 
redistribution of body mass due to changes in fat tissues not 
involving bone or muscle tissues. Fat redistribution more 
frequently with triple therapy including a PI than with duo 
therapy with NRTIs. Women with fat redistribution shows 
cytokine pattern (high IL-12, low IL-10 and TNF) not seen in 
women without fat redistribution, but no differences between 
groups observed with respect to plasma cortisol, ACTH, GH, 
C-peptide, testosterone, prolactin, glucose, cholesterol, or TG 
levels.  
Adapted from Graham 2000  
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2.2 METABOLIC DISEASES 
 
The metabolic diseases such as hypertension diabetes mellitus, obesity and 
hypercholesterolemia are predominantly found in developed countries. 
However, the prevalence’s are gradually increasing in the developing 
countries. There are various factors contributing to this, such as urbanization 
and western lifestyle. Recently the HIV and its treatment are also linked to 
that.    
 
2.2.1 METABOLIC DISEASES AMONG HIV INFECTED PATIENTS 
 
Longer duration of protease inhibitor therapy, HIV stage (those who started on 
HAART later on in the course of their disease) as well as increased CD4 
count and decreased viral load are associated with the risk of developing 
diabetes mellitus, dyslipidaemia and hypertension (1). Demographic and 
anthropometric characteristics such as age, gender and ethnicity was found to 
be associated risk factors of the mentioned metabolic diseases (1;3). 
 
 Older age and male gender were significantly associated with dyslipidaemia 
in study of a cohort of 900 HIV positive patients (1). It was also found that the 
risk of developing diabetes mellitus increased with older age and when 
patients on HAART were overweight or obese (17).  
 
2.3 DIABETES AND ABNORMAL GLUCOSE METABOLISM  
 
The prevalence of diabetes in the general population in South Africa is estimated at 
between 2.8% and 3% and is expected to increase to 3.9% by 2025; this expected 
increase is linked to the worldwide increase in obesity. (18).      
 
2.3.1 DIABETES AMONG HIV POSITIVE PATIENTS  
 
Glucose metabolism alterations are frequent in HIV-positive individuals 
treated with ART and give impetus to insulin resistance, impaired glucose 
tolerance, and diabetes mellitus (3;19). As a result of that, the incidence of 
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diabetes mellitus is increasing in the HIV infected population more than that of 
the general population, even in the absence of the concomitant problem of 
obesity (20). Both in vitro and clinical studies have shown that PI even after a 
single dose can induce insulin resistance (4;21) which underlies many 
metabolic conditions including type 2 diabetes (4;22) 
 
One study have illustrated that the prevalence of diabetes mellitus in PI 
recipients with lipodystrophy have increase from 2% to 7% after 14 months 
observation (23). The overall prevalence of glucose disorders in HIV-infected 
patients treated with HAART, which includes diabetes mellitus, impaired 
fasting glucose and impaired glucose tolerance, was found to be at 25% for 
that particular study (23). 
 
Prospective studies have reported that 10% of HIV infected patients treated 
with HAART developed diabetes during 4 years of follow-up (4;24). 
 
2.4 DYSLIPIDAEMIA 
 
Dyslipidaemia has been noted as one of the major contributing factors of 
cardiovascular diseases in the South African population and is expected to be 
exacerbated by the increase of diabetes and obesity, also known as diabesity 
(25). The prevalence of lipid abnormalities in South Africa has not been 
determined in a population samples, by means of a national survey or by 
other data collecting tools, although smaller random studies has been 
conducted (25).  
 
 
2.4.1 DYSLIPIDAEMIA AMONG HIV POSITIVE PATIENTS  
 
Increasing incidence of dyslipidaemia has been recognised among HIV 
infected individuals. HIV infection per se is associated with lipid alteration 
including total cholesterol and it components (low HDL- and LDL-cholesterol 
and hypertriglyceridaemia) (4). The use of HAART has been associated with 
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elevation of serum lipids above that of its pre-treated levels, except for HDL 
cholesterol  (1;26).  
 
The prevalence of dyslipidaemia in HIV infected patients ranges from 28% to 
80% and includes hypertriglyceridedaemia (40-80%), hypercholesterolemia 
(10-50%) and mixed forms (26). Insulin resistance has been considered the 
link between dyslipidaemia and other metabolic disturbances within metabolic 
syndrome such as abdominal obesity, diabetes, heat diseases, hypertension 
(4). 
 
There has been no association found between CD4 lymphocyte count or viral 
load and lipid abnormalities (27). Due to the high incidence of dyslipidaemia 
and its potential long term morbidity in this population, it is deemed necessary 
to screen HIV patients on HAART for lipid abnormalities (27).  
 
2.5 HYPERTENSION  
 
Hypertension in South Africa is a very common condition and is a risk factor 
for cardiovascular diseases. There are various definitions of hypertension 
such as South African guidelines for Hypertension, WHO etc. The most widely 
used definition is that of the systolic blood pressure of > 140 mmHg and 
diastolic pressure of > 90 mmHg.  People who are hypertensive are usually 
unaware of that they have this condition unless their blood pressure has been 
measured at a healthcare facility (28). According to the  second South Africa 
Demographic and Health Survey (29), the reported prevalence of 
hypertension in men was 9% and 19% in women, but this prevalence rose 
significantly when they were identified as either hypertensive (blood pressure 
 140/90 mmHg) or on hypertension medication, to 40% in men and 51% 
women for  the age group 15 and older (29).  This analysis was made by 
means of making use of the South African hypertension guidelines and the 
WHO international Society of Hypertension Guidelines for the Management of 
Hypertension that suggest that a person can be  classified as being 
hypertensive with a blood pressure BP 140/90 mmHg, and/or taking anti-
hypertensive medication (28).   
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2.5.1 HYPERTENSION AMONG HIV POSITIVE PATIENTS  
 
HIV-infected patients are at a higher risk of developing hypertension 
compared to the general population. The prevalence of hypertension in HIV 
infected people is 29% and occur more in older men than in women (30). 
Body mass index (BMI), in this group has been reported to be significantly 
higher in the hypertensive individuals compared to the normotensive group 
(25.8 vs. 23.6 kg/m2 (30).  
 
The prevalence of hypertension in HIV infected patients that is on HAART 
was found to be 21% in one study (31). Hypertension was found to be more 
prevalent in males than in females (17;30;31).  
 
It was also noted that the time interval between the onset of symptoms and 
the establishment of components of hypertension such as, pulmonary 
hypertension was approximately six months  which is in contrast with 
diagnoses of pulmonary hypertension in which that time has been reported as 
2.5 years (31;32). Therefore, the HIV infected patients on HAART should be 
monitored closely for hypertension. 
 
2.6 OBESITY  
 
Obesity has become a global epidemic with an estimated 1.3 billion people 
overweight or obese (31;33). The developed countries have higher 
prevalence obesity and overweight than developing countries, with the United 
States with a prevalence of 26.6% in men and 32.2% in women above 20 
years of age. The epidemic is however on the increase in the developing 
countries. The second South African Demographic and Health Survey 
(SADHS), undertaken in 2003 and published in 2004, indicates that the 
prevalence of obesity for adult men is 9% and 23% for adult women while the 
prevalence of overweight is found to be at 21% for men and 29% for women 
(29).   
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2.6.1 OBESITY AMONG HIV POSITIVE PATIENTS  
 
The prevalence of Obesity in HIV infected individuals was reported at 14% 
and was found to be more common in women than in men. A CD4 lymphocyte 
count  200 cells/µL count is associated with an increase in BMI. (15) 
 
2.7 METABOLIC SYNDROME  
 
Metabolic syndrome which is affecting the general population in epidemic 
proportions is commonly associated with increase cardiovascular risk (34). 
The risk of metabolic syndrome has been found to be greater in HIV infected 
patients compared with that of the general population because of the higher 
prevalence of lipid and glucose abnormalities (35) 
 
2.7.1 METABOLIC SYNDROME AMONG HIV POSITIVE PATIENTS  
 
The prevalence of metabolic syndrome in HIV infected individuals has been 
reported at 14% to 20.8% (4;35). In a study population of 881 HIV infected 
patients it was found that progression to metabolic syndrome occurs within 
three years after the initiations of antiretroviral therapy and the incidence of 
this syndrome was significantly associated with an increased risk of diabetes 
mellitus and cardiovascular diseases (3).  
 
The age and gender risk- adjusted risk of having metabolic syndrome in HIV 
infected patients was twice as great as that in HIV-negative control patients 
(5;35;36). 
 
The development of metabolic syndrome in patients treated with HAART is an 
inevitable consequence of long-term successful HAART (37). Therefore, the 
HIV-infected patients on HAART must be monitored for metabolic syndrome 
in order to manage this added burden of disease effectively.   
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2.8 SUMMARY OF THE CHAPTER  
 
South Africa is afflicted by a quadruple burden of disease, including 
HIV/AIDS, cardiovascular diseases, infectious parasitic disease, malignant 
neoplasm and injuries  (12). The review of literature confirms that metabolic 
and morphological changes, as a result of the prolong use of HAART, are 
prevalent among HIV positive individuals. Thus, the quadrants between the 
cardiovascular diseases as described above and the HIV/AIDS will blur more 
in future as more HIV-infected patients are expected to receive HAART.    
 
Figure 2.3: Projected burden of disease due to the effect of HAART 
 
The mechanism of developing of metabolic diseases among HIV infected 
individuals is not yet well understood.  
 
Furthermore, the burden of metabolic disease among HIV infected individuals 
on HAART has not been fully explored in South Africa.  
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CHAPTER 3 
 
METHODOLOGY 
 
The methodology used for this study was selected on the basis of its aims and 
objectives. In this chapter the following are discussed: setting, scope, study 
design and research tools.  
 
The motivation for this study was driven by the need to estimate the burden of 
HIV associated metabolic diseases in public hospitals in South Africa, which 
has one of the highest prevalence of HIV/ AIDS in the world. In this chapter 
the study design, scope, study population, sample size calculation, research 
tools, the data collection, the pilot study, analysis and statistical methods are 
described.  
 
3.1 STUDY DESIGN 
 
The study design was a cross-sectional study of HIV positive patients that 
have developed metabolic disorders, specifically looking at diabetes, 
hypertension, obesity and dyslipidaemia.  
 
3.2 SETTING  
 
This study was conducted at the Charlotte Maxeke Johannesburg Academic 
Hospital (JHBH) in the Gauteng province of South Africa (Figure 3.1) 
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Figure 3.1: The Province of Gauteng 
 
The JHBH have a HIV clinic which caters for the HIV positive patients 
Southern surrounding areas of Johannesburg. This hospital has been chosen 
because it is one of the first hospitals in South Africa to have been accredited 
to roll-out ARV treatment. Thus, the mean number of years for patients that 
were recruited was three years.  
 
3.3 SCOPE 
 
This study was a prospective study on HIV positive patients attending the 
JHBH HIV clinics.  
 
3.4 STUDY POPULATION 
 
The study population was the HIV positive patients at the JHBH HIV clinic that 
was on HAART for more than one year at the time of the study. Patients that 
were not on HAART or that were on HAART for less than a year was 
excluded. Only patients between the ages of 18 and 45 years were recruited 
for this study. This was due to the fact that metabolic diseases general occurs 
in people above the age 45 years and thus the HAART might have little 
impact on the development of metabolic diseases. Patients under the age of 
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18 years can only participate, provided that permission was obtained from 
their parents or guardians.  
 
3.5 SAMPLE SIZE 
 
Sample size was calculated using Statcalc (Epi-Info version 6) based on: 
• a study population of 1500 
• expected prevalence of 50%, and  
• worst acceptable result of 45% 
•  of 0.05 and  of 0.8. 
A sample size of 304 was required to achieve the above parameters.  
  
Study variables 
The following variables were collected for each patient:  
• Demographic information – gender and age (The DISA system does not 
record the patients ethnicity) 
• Metabolic disorders: types and prevalence  
• Duration of HAART  
• Diabetes: blood sugar  
• Cholesterol triglyceride, HDL-cholesterol   
• Body mass index and waist circumference  
• Blood pressure measurements  
The sources of the above variables are listed in Table 3.1. 
 
 
 
 
 
 
 
 
 
 
 
  19   
Table 3.1: Data source for variables 
Objectives Variables  Data  Source  
2 age  
2 gender   
Waist Circumference  Patient file   
BMI (kg/m2) Patient file 
Systolic Blood pressure  Patient File   
Diastolic Blood pressure Patient File 
total cholesterol DISA*Lab  & Patient file 
LDL cholesterol  DISA*Lab  & Patient file 
1 
Triglycerides  DISA*Lab & Patient file  
 HDL Cholesterol  Male DISA*Lab & Patient file 
 HDL Cholesterol  female  DISA*Lab & Patient file 
Glucose  DISA*Lab & Patient file 1 
HBA1c  DISA*Lab & Patient file 
 
• Metabolic syndrome: For the purpose of this study metabolic syndrome 
is defined according to the international diabetes federation (IDF) 
criteria, which includes waist circumference >80 cm in women and >94 
cm in men plus two of the following: triglycerides > 1.7 mmol/l, HDL 
<1.29 mmol/l, systolic blood pressure 130 mmHg, or diastolic blood 
pressure  85 mmHg. No data for fasting glucose were used as these 
are not done routinely. 
• Hypertension:  For the purpose of this study hypertension was defined 
as blood pressure > 140/90 and / or if the patient were on hypertensive 
medication. 
• Diabetes mellitus: For the purpose of this study diabetes mellitus was 
defined as an HBA1C > 7% or a random glucose  11.1 mmol/l. 
• Dyslipidaemia: For the purpose of this study hypercholesterolemia was 
defined as Total Cholesterol (TC) > 5.0 mmol/l, (TC  6.2 mmol/l IDF 
criteria for MS), LDL Cholesterol (LDL)  4.1 mmol/l, HDL Cholesterol 
(HDL)  1.2 mmol/l,  Triglycerides  1.7 mmol/l 
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3.6 DATA COLLECTION  
 
The data was collected over three months  period (January 2009 to March 
2009) by means of reviews of the patients files and the NHLS laboratory 
information system (DISA*LAB) using the patients’ hospital-numbers. The 
researcher visited the HIV clinic of the JHBH each day of the study period. He 
approached the patients who fulfil the inclusion criteria and obtained their 
consent to do laboratory blood tests and anthropometric measurements.   
 
Patients receiving HAART for more than one year, at the time of the study 
was asked to volunteer to have their anthropometric measurements taken and 
their blood drawn for relevant tests. The laboratory tests that were done for 
these patients include HIV viral loads, CD4 lymphocytes counts, Lipograms, 
Glysated Haemoglobin (HbA1c) and random glucose test.  
Data collection tools are described below in Table 3.2.  
 
Table 3.2: Data Collection tools 
Tools name Data Collection 
tool 
Patient clinical records 1 
Metabolic profile of HIV patients 2 
HIV related tests 2 
 
 
3.7 DATA ANALYSIS 
 
The hospital-numbers of the HIV-infected patients was supplied by the 
management of the JHBH-HIV clinic. The collected data was recorded by 
making use of Microsoft access. Each patient’s information regarding their 
age, sex, BMI, waist and Hip circumferences and the interested laboratory 
results (HBA1C, random sugars, Lipograms including TC, HDL, LDL and 
plasma triglycerides) was recorded. 
 
Patients’ results were obtained from the NHLS laboratory information system 
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and were verified against their respective hospital patient files.  
All data was analysed using standard statistical software Epi-info version 6.0.  
 
Following descriptive statistics was reported: 
• continuous variables with normal distribution: mean and standard deviation  
• Other continuous variables: median and interquartile range, and  
• Nominal and ordinal variables: proportion and range. 
 
Following analytical statistics was reported 
• For two samples and one variable:  
o Continuous variables with normal distribution: t test 
o Other continuous variables: Mann-Whitney’s test  
o Nominal and ordinal variables: Chi-Square test  
• For two samples and two variables: Analysis of Variance  
• Logistics regression was used to determine the factors influencing the 
prevalence of metabolic syndrome 
 
3.8 PILOT STUDY  
 
A pilot study, on retrospective data, was conducted to test the feasibility of the 
study.  The JHBH HIV clinic database was used to screen 194 patient’s files 
of patients that have received HAART for more than one year. The pilot study 
indicated that 115 (59.28%) of 194 patients were tested for the relevant 
metabolic disease.  The pilot study further indicated that the relevant data for 
the project was very scanty. The anthropometric data for most the patients 
(90%) were also not complete. The Table 3.3 depicts this sparseness the 
laboratory data of the patient’s that were screened.  
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Table 3.3: laboratory data for patients on HAART prior 2006 
Number of Patients files 
screened  Laboratory tests Total (%) 
194 Total no of relevant metabolic tests 115 (59.28) 
194 Random Glucose  7 (3.6) 
194 Fasting Glucose 2 (1.0) 
194 Glysated Haemoglobin (HBA1c)  3 (1.6) 
194 LDL cholesterol 8 (4.1) 
194 HDL cholesterol  8 (4.1) 
194 Triglycerides 50 (25.8) 
194 Total cholesterol 62 (31.9) 
 
The paucity of data prompted the researcher to obtain further permission to 
collect the required data prospectively from patients’ files.  
 
3.9 ETHICAL CONSIDERATIONS  
 
This project was approved by the committee for Human Subjects Medical 
(M081154) and the Management of Johannesburg Hospital. (Annexure A and 
B) 
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CHAPTER 4 
 
RESULTS 
 
The results obtained from the analysis of the data are described in this 
chapter.  
 
4.1 STUDY SAMPLE    
 
A total of 345 study participants partook in the study but only 304 patients had 
all the relevant metabolic tests done. The study population consist of 237 
(77.9%) female and 67 (22%) male participants.  
 
4.2 DEMOGRAPHIC INFORMATION  
 
The study participants comprised of patients at the JHBH HIV clinic that were 
on HAART treatment for more than one year at the time of the study and 
between the ages of 18 and 45 years. Age was distributed normally and the 
mean age for the study group was 35.8 ± 5.3 years. The mean number of 
years that patients were receiving HAART is 3.2 ± 2.4 years. The mean 
number of years that male and female participants received HAART did not 
differ very much with a mean of 3.14 years for female and a mean of 3.53 
years for male. The range of the study group was between 23 and 45 years of 
age.  
 
Table 4.1: Age distribution and the period on HAART  
 Total (Mean ±SD) Female (Mean ± SD) Male (Mean ±SD) 
Sample size 304 237 67 
Age 35.8 ±5.3 37.4 ± 4.4 35.4 ± 5.5 
Number of 
HAART Years 
3.2±2.4 3.1±1.5 3.53±4.3 
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4.3 ANTHROPOMETRIC MEASUREMENTS   
 
Among the 304 participants, 152 (50%) met the criteria for IDF abdominal 
obesity threshold levels, that includes 7 (10%) men that had a waist 
circumference > 94 cm and 145 (61%) women that had a waist 
circumferences > 80 cm. Less patients however, met the threshold levels for 
the NECP (ATP) III criteria, in that only 88 (30%) of participants, including 4 
(6%) men and 84 (34%) women met the criteria of a waist circumference > 88 
cm for women and 102 cm for men.  
 
Table 4.2: Anthropometric Measurements  
  Total (Mean ±SD) 
Female (Mean ± 
SD) Male (Mean ±SD) 
Waist (cm) 84.2  ± 11.5 84.8 ± 12.0 82 ± 9.7 
HIP (cm)  99.5 ± 11.5 100.8 ± 12.1 94.7 ± 6.9 
Weight (kg)  66.8 ± 13.5 66.6  ± 14.1 67.7 ± 10.9 
 
4.4 BODY MASS INDEX  
 
The World Health Organization (WHO) standards were used to categorise 
body mass index. Table 4.3 depicts the distribution of the weight categories 
for the sample population. The mean BMI of the study group was 25.15 ± 5.3 
kg/m2 with a mean BMI for women of 25.76 ± 5.6 kg/m2 and men mean BMI = 
23.07 ± 3.2 kg/m2. There is no correlation between BMI and Viral load 
(Spearman’s correlation  = 0.01; p=0.95). Therefore a high BMI is associated 
with a low viral load. There is a significant positive correlation between BMI 
and CD4 lymphocyte count (Spearman’s correlation  =0.12; p =0.02). 
Therefore, BMI is associated with higher CD4 lymphocyte count.  
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Table 4.3: Body Mass Index (BMI=kg/m2) 
Category  Total (%) Female (%) Male (%) 
Obese  
(BMI 30 kg/m2) 51 (16.8%) 47 (19.8%) 4 (5.9%) 
Over weight  
(BMI 25 < 29.9 kg/m2)  87(28.6%) 73 (30.8%) 14 (20.9%) 
Normal Weight  
(BMI 18.5<24.9 kg/m2)  145 (46.8%) 97 (40.9%) 48 (71.6%) 
Under weight  
(BMI<18.5 kg/m2)  15 (4.9%) 13 (5.5%) 2 (2.9%) 
 
4.5 DYSLIPIDAEMIA  
 
The International Diabetes Federation (IDF) was used to categorise the lipid 
profiles as depicted in Table 4.4.  The mean total cholesterol (TC) levels for 
the study group were 4.7± 1.0 mmol/l. On the IDF definition of TC> 6.2 mmol/l 
there was more women that met this criteria than men. The prevalence for 
hypercholesterolemia (TC  5 mmol/l, the clinical cut-off as determined by the 
National Health Laboratory Services (NHLS)) is 35.5% (n=108) for the study 
group, (n=83) 35% women and 37% (n=25) in men.  The overall mean for 
HDL–cholesterol was 1.2 ± 0.4 mmol/l and the overall mean for LDL 
cholesterol was 2.8 ± 0.9 mmol/l.  
 
Table 4.4: Lipid Profiles  
Category  Total (%) Female (%) Male (%) 
Total Cholesterol >6.2  mmol/l 24(8%) 18(6%) 6(2%) 
HDL <1.29 mmol/l  Female  138(58%) 138(58%) 0 
HDL <1.04 mmol/l male 24(36%) 0(0) 24 (36%) 
Triglycerides>1.7 mmol/l 90(30%) 61(26%) 29(14%) 
LDL > 4.1 mmol/l 32(10%) 27(11%) 5(7%) 
Patients lipid lowering drugs 25(8.2%) 16(5.8%) 9(13.4%) 
 
 
 
  26   
4.6 BLOOD SUGARS AND DIABETES  
 
Only 1% of the study population had random glucose levels higher than 11.1 
mmol/l and same percentage that had an HbA1c >7%. All these patients were 
more than 30 years of age.  No patients were tested for fasting glucose.  
 
Table 4.5: Blood Sugars  
Category  Total (%) Female (%) Male (%) 
HbA1c >7% 4(1%) 4(2%) 0 
Random Glucose >11.1 mmol/l 4(1%) 4(2%) 0 
 
4.7 HYPERTENSION  
 
Hypertension (systolic / diastolic  140/90 mmHg and / or on hypertension 
medication) was reported at 16% in this study population and was more 
prevalent in males (17.9%) than in females (13.9%).  
 
Body weight was significantly associated with systolic and diastolic blood 
pressure (Spearman’s correlation  =0.26; p <0.001 and Spearman’s 
correlation  =0.23; p <0.001 respectively).  Similarly, body mass index was 
significantly associated with systolic and diastolic blood pressure (Spearman’s 
correlation  =0.21; p <0.001 and Spearman’s correlation  =0.20; p <0.001 
respectively).   
 
Table 4.6: Blood Pressure  
Category  Total (%) Female (%) Male (%) 
Systolic/Diastolic >140/90 mmHg 18 (6%) 12(5%) 6(9%) 
Systolic/Diastolic >140/90 mmHg + 
Hypertension drugs 
11(3.6%) 7(2.9%) 4(5.9%) 
Systolic/Diastolic >140/90 mmHg with no 
Hypertension medication (Undiagnosed) 
7(2.3%) 5(2.1%) 2(3%) 
Total Patients on Hypertension 
medication 
43(14%) 33(13.9%) 10(14.9%) 
Total Hypertensive Patients  50(16%) 38(16.03)  12(17.9%) 
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Systolic >130 / Diastolic > 85 mmHg (IDF 
criteria for MS) 
43(14%) 29(12%) 14(21%) 
 
 
4.8 METABOLIC SYNDROME  
 
Table 4.7 indicates that 20.4% of participants met the metabolic syndrome 
criteria for IDF definitions. At least two features of metabolic syndrome, 
excluding their waist circumferences that was in the non-metabolic range, 
were present in 17 (25%) men and 48 (20%) women respectively, in the study 
group.  
 
Table 4.7: Metabolic syndrome according to IDF criteria  
  Total  Female  Male  
IDF  62(20.4%) 57(24.1%) 5(7.5%) 
 
 
4.9 FACTORS INFLUENCING METABOLIC SYNDROME  
 
The logistic regression analysis shows a significant association between the 
various variables and metabolic syndrome (P < 0.0001). The age has a 
positive association and the women had more chance of developing metabolic 
syndrome. The CD4 count had near significant association. However, viral 
load and period on HAART had no significant association with metabolic 
syndrome.    
 
4.10 HIV RELATED LABORATORY TESTS  
 
The majority of the patients 263(86.2%) had a CD4 lymphocyte count for  
200 x 106 cells/l, which includes 212(89.5%) women and 51(76.1%) men.  
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Table 4.8: CD4 lymphocyte count 
 Laboratory 
Test Total  (Mean ±SD) Female (Mean ± SD) Male  (Mean ±SD) 
CD4 
lymphocyte 
 (106 cells/l) 
416.1± 203.7  441.9±208.9 323.4±152.4 
 
Most of the patients HIV viral load tests results were less than detectable; viral 
load < 40 copies /µl. 
 
Table 4.9: HIV RNA Viral load  
Category  Total (%) Female (%) Male (%) 
LDL (VL< 40 RNA copies/ ml) 255 (84) 201 (85) 54 (81) 
Viral Load VL 40 RNA copies/ ml 49 (16) 36 (15) 13 (19) 
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CHAPTER 5 
 
DISCUSSION 
 
 
In this chapter, the results obtained in the previous chapter is discussed and 
compared with other published studies. 
 
5.1 INTRODUCTION  
 
This study was an attempt to explore the burden of metabolic diseases among 
HIV patients that received HAART for period of more than one year at JHBH 
HIV clinic.  
 
The findings in this report are based on data that was collated from patients’ 
anthropometric measurements, metabolic and HIV related laboratory tests 
results. The data was collected from consented patients of whom their 
anthropometric and laboratory tests results were obtained. Only patients that 
were older than 18 years and younger than 45 years and on HAART for more 
than one year, at the time of the study was allowed to partake in the study. A 
total number of 345 patients volunteered but only 304 patients participated in 
the study.  
 
5.2 RISK FACTORS AND PREVALENCE OF METABOLIC 
DISEASES AMONG HIV PATIENTS 
 
It is well documented that the use HAART has significantly decreased the 
morbidity and mortality rate of HIV infected individuals (26). The South African 
Government, however only made these drugs available in 2004, hence the 
mean number of years that male and female patients were on HAART, for this 
study was 3.5 and 3.1 years respectively. The prolong use of HAART (that 
contains PI), age, sex, increased CD4 count and decreased viral load  is 
associated with increased risk of developing metabolic diseases, (such as 
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obesity, Hypertension, diabetes mellitus, dyslipidaemia, and metabolic 
syndrome) (1;3;17).  
 
The present study confirms that these metabolic diseases are more prevalent 
in women, except for hypertension where the prevalence were higher in men 
than in women. The concentration levels of HIV viral load for the majority of 
patients (84%) were within the undetectable limits (VL<40 copies / µl) along 
with 86.2% of the patients that had their CD4 lymphocyte  200 X 106 cells/l. 
These ranges for CD4 lymphocytes and viral loads was reported to be 
optimum levels for the impetus of the relevant metabolic diseases (38;39). 
 
5.3 DIABETES  
 
The prevalence of diabetes in HIV infection is expected to vary from one 
population to another as being modified by factors such as genetic 
susceptibility, obesity rates and sedentariness (40). Only 4(1%) of the study 
population had an HbA1c>7% and random glucose > 11.1 mmol/l, and all of 
them were also women. This is much lower than the reported diabetes of 23% 
to 40% for HIV positive patients (23). Prospective studies have reported that 
10% of HIV infected patients treated with HAART developed diabetes during 4 
years of follow-up (4;41). The prevalence of hyperglycemia for a study done in 
1440 HIV-infected patients was reported at 2% (42).  
 
The prevalence for diabetes and glucose impairment for this study was also 
lower than both the national and provincial prevalence for women that have 
diabetes in the general population of SA and Gauteng.  
 
Diabetes mellitus was reported to be at 2.9% nationally for the age group 
between 35-44 years and 3.5% for the province of Gauteng in 2003 (29). The 
prevalence of diabetes mellitus for the same age category for this study was 
found to be n=3 (2.32%) of women. None of the four patients that were 
diagnosis with diabetes mellitus in this study was on HAART for more than 4 
years.  
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5.4 OBESITY AND OVER WEIGHT   
 
The data for this study suggest that obesity and overweight is more prevalent 
among women than in men. This data correlates with previous reported data 
(15). BMI 30 kg/m2 is associated with increased CD4 Lymphocyte count and 
decreased viral load as what was reported previously (15).  The prevalence 
for obesity for this study (16.8%) was higher than that reported for patients on 
HAART at 14% (15).  
 
However, the prevalence for obesity for women (20.9%), for the ages between 
35 and 44 years, for this study group is much lower than that of the reported 
35.4% obesity for women between the ages of 35-44 years in general 
population for South Africa (29). The prevalence for obesity in the Gauteng 
province  was found to be 30.1% in 2003 (29),  which is also higher than the 
prevalence for this study group. In 2003 the SADHS reported  that obesity in 
South Africa was more prevalent among older women and men and that the 
prevalence among women, African, Coloured and Asian were most likely to 
be equal to be obese (29). Due to the race composition of the patients JHBH 
HIV clinic it was not possible to affirm these findings.  
 
5.5 HYPERTENSION  
 
Hypertension in South Africa is a very common condition and is a risk factor 
for cardiovascular diseases. According to the second South Africa 
Demographic and Health Survey (SADHS 2003), the total national prevalence 
of hypertension in men was 40% and 51% in women for the age group 15 and 
older and the prevalence for the Gauteng province was 9.2% for men and 
21.2% for women   (29).   
 
HIV infected patients are at a higher risk of developing hypertension 
compared to the general population (30). Patients were classified as 
hypertension when they had a blood pressure reading (BP) 140/90 mmHg 
and / or were on hypertension medication.  The data for this study indicates 
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that 16% of the study population met this criterion and is therefore said to be 
hypertensive. This prevalence of hypertension in this HIV infected patients is 
much lower than the 29% that what was previously reported for HIV positive 
patients (30). More men (17.9%) than women (16.03%) were classified as 
being hypertensive. This study found that 7 (2.3%) of this study population 
was undiagnosed for hypertension as they were not on anti-hypertension 
medication.  
 
The prevalence of hypertension in this study group was lower for women 
(15%) and  higher for men (24%) than that found in the general population of 
South Africa, where the national prevalence for women and men between the 
ages of 35 and 44 were, 18.8% and 8.8% respectively (28;29). The 
prevalence is higher for men in the Gauteng province where the prevalence 
was 9.2 % for men and  still lower for women  where the prevalence were 
21.3% in 2003 in the same age category (29). 
 
5.6 DYSLIPIDAEMIA  
 
Lipid metabolism abnormalities have been increasingly recognized among 
HIV-infected patients treated with HAART (1;26). Dyslipidaemia is therefore 
very common among HIV positive people that are on (HAART) (27;39) and 
the prevalence ranges between 33% and 82% (26;27). The prevalence of 
dyslipidaemia in our study group ranges between 10% for LDL > 4.1 mmol/l 
and 58% for HDL<1.29 in women. The prevalence of triglycerides>1.7 mmol/l 
was 34% compared with the documented prevalence ranges between 43% 
and 66% (3;27). Data from a prospective cohort study reported that 19% of 
patients develop hypertriglyceridedaemia and 24% of patients develop 
hypercholesterolemia after 5 years of HAART (3). In the current study the 
prevalence for hypercholesterolemia is 35%. This prevalence is much higher 
than the reported 19.4 % for Black Africans in South Africa (43). The data for 
this study did not find any association between CD4 lymphocyte count or HIV 
viral load and lipid abnormalities. This is also a reinforcement of previous 
reported data (27;39).    
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The presences of lipid abnormalities in this study were more prevalent in 
women than in men.  
 
The prevalence for dyslipidaemia in South Africa has not been determined in 
a random population sample through national surveys (25). Various studies 
have been conducted in smaller regional surveys (25); however the data was 
not used to draw any comparisons as these regions were all outside the 
province of Gauteng. 
 
 
5.7 METABOLIC SYNDROME  
 
Metabolic syndrome which is affecting the general population in epidemic 
proportions is commonly associated with increase cardiovascular risk (34). By 
using the IDF criteria for metabolic syndrome, 20.4% of the patients can be 
classified as being positive for metabolic syndrome. Many patients who were 
not classified as having metabolic syndrome had at least two metabolic 
syndrome components, including low HDL and BP  130/85 mmHg but did not 
meet the criteria for the waist circumferences. Women had a higher 
prevalence of metabolic syndrome than men. 
 
The prevalence of metabolic syndrome, among HIV positive patients, in an 
international cohort study, was reported at 14% using the IDF criteria and 
18% using the NCEP (ATP) III criteria (6). The prevalence for metabolic 
syndrome in this study group is much higher than the reported data for HIV 
patients (6;37).  
 
The data suggest that age and female gender is associated with the 
development of metabolic syndrome among HIV patients on HAART. CD4 
count had a near significant association, while viral load and period on 
HAART had no significant association with the development of metabolic 
syndrome.   
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 By comparing this findings with that of prevalence studies done in the general 
population of South Africa the prevalence according to the IDF criterion was 
lower 20.4% vs. 24.8% (37;44). 
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CHAPTER 6 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
This chapter concludes the research report and draws conclusion from the 
research data in relation to the aim of the study and makes recommendations 
regarding the need to test HIV positive patients for metabolic related disease. 
The limitations of the study are also articulated and recommendations for 
further studies that stems from the limitations is also made.  
 
6.1 CONCLUSIONS ACCORDING TO THE OBJECTIVES OF THE 
STUDY 
 
The following conclusions are made according to the findings of this study: 
 
Objective 1: Determination of the prevalence of metabolic diseases 
(hypertension, diabetes, obesity and dyslipidaemia) in patients 
attending the HIV clinics at JHBH  
 
This study found that the prevalence of diabetes mellitus is 1%, hypertension 
is 16%, obesity is 16.8%, and hypercholesterolemia is 35.5% among HIV 
positive patients in the age group 18 to 45 years and on HAART medication 
for more than one year.   
 
Objective 2: Determination of the prevalence of metabolic syndrome 
among patients attending the HIV clinics at JHBH  
 
This study found that the prevalence of metabolic syndrome, according to the 
IDF criteria, is 20.4% among HIV positive patients that is on HAART 
medication for more than one year and between the age of 18 and 45 years.  
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Objective 3: Determination of the association between specific risk 
factors (such as: age, gender, CD4 lymphocyte count, viral load) and 
metabolic syndrome in HIV infected patients  
 
This study found that the development of metabolic syndrome was positively 
associated with age and that female gender has a greater chance of 
developing metabolic syndrome. CD4 had a near significant association. 
However viral load and the period on HAART had no significant association 
with the development of metabolic syndrome.   
 
 
6.2  LIMITATIONS  
 
The findings of this study may not be generalisable to all age categories and 
all racial groups, as the majority of the sample were mainly black African 
females.  
 
Metabolic syndrome for this study was defined without fasting glucose tests 
done for the patients and was determined based on the remaining 
parameters, i.e. waist circumferences, low HDL, elevated plasma triglycerides 
and BP  130/85 mmHg.  
 
Furthermore, there were no age and sex match controls included i.e. patients 
that were HIV negative and patients that were HIV positive, but not on 
HAART.  
 
 
6.3 FURTHER RESEARCH  
 
 The following is proposed for further research:  
 
1. A randomized control study to compare a) HIV positive patients on HAART 
with b) HIV positive patients without HAART medication and c) HIV 
negative patients to estimate the true effect of HIV and HAART on the 
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prevalence of metabolic diseases and metabolic syndrome.  
 
2. A longitudinal study among HIV patients on HAART to establish the 
incidence of metabolic diseases and metabolic syndrome.  
 
6.4 SUMMARY OF THE STUDY  
 
The findings of this research indicate that there is a high prevalence of 
metabolic syndrome among HIV patients that is on HAART for more than one 
year in this study group.  
 
These metabolic diseases are negatively correlated with CD count and viral 
load and were more frequent in women than in men, except for hypertension. 
Literature review indicates that the development of metabolic disorders is 
associated   prolong use of HAART in HIV positive patients.  
 
It is therefore recommended that a longitudinal study needs to be conducted 
to monitor all patients on HAART, at the JHBH HIV clinic for metabolic 
disorders.  
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